http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
The Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery
-
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease
-
AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress
-
AbbVie Announces Public Voting Open for 30th Annual Cystic Fibrosis Scholarship "Thriving Student Awards"
-
Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories
-
AbbVie (ABBV) Reports New Data from Phase 3 Trials of SKYRIZI
-
New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100
-
AbbVie Declares Quarterly Dividend
-
New MEASURE-AD Analyses Evaluate Clinical, Psychosocial and Economic Burdens in Atopic Dermatitis Patients
-
AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022
-
Allergan Aesthetics Celebrates 100 Million Syringes of JUVÉDERM®
-
AbbVie to Present at the Morgan Stanley Healthcare Conference
-
Ironwood Pharma (IRWD) Announces Positive Phase III Trial of LINZESS in Patients 6-17 with FC
-
SkinMedica® Launches Firm & Tone Lotion for Body
-
AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress
-
Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)
-
Experience the JUVÉDERM® Difference with Allergan Aesthetics
-
AbbVie (ABBV) Announces FDA Approves JUVEDERM VOLUX XC for Improvement of Jawline Definition
-
FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition
-
Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases
-
AbbVie Reports Second-Quarter 2022 Financial Results
-
AbbVie (ABBV) Announces EU Approval of RINVOQ as Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis
-
RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis
-
AbbVie (ABBV) Submits Regulatory Applications to FDA and EMA for Upadacitinib in Crohn's Disease
-
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's Disease
-
AbbVie (ABBV) Announces EU Approval of RINVOQ for Treatment of Adults With Moderate to Severe Ulcerative Colitis
-
European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis
-
AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference
-
AbbVie (ABBV) and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
-
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
-
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-
-
Genmab (GMAB) Announces That AbbVie (ABBV) Will Submit MAA to EMA for Epcoritamab for the Treatment of R/R DLBCL
-
AbbVie (ABBV) Submits European Marketing Authorization Application for Atogepant
-
AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine
-
AbbVie to Host Second-Quarter 2022 Earnings Conference Call
-
Approximately 15,000 AbbVie Employees to Volunteer Globally to Support Local Communities in Annual Week of Possibilities
-
CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis
-
New Survey Offers Perspective on Mental and Emotional Journey for Patients Diagnosed with Slow-Growing Blood Cancer
-
AbbVie Declares Quarterly Dividend
-
AbbVie (ABBV) Submits Supplemental NDA to U.S. FDA for Atogepant to Support Label Expansion for the Preventive Treatment of Migraine
-
AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine
-
AbbVie (ABBV) Announces SKYRIZI Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
-
SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
-
AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematolo
-
AbbVie (ABBV) Reports Five-Year Follow Up VENCLYXTO/VENCLEXTA Data Demonstrating 60% of Patients Show Longer PFS
-
AbbVie (ABBV) Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients
-
AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients
-
New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment
-
AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® (AHS) Annual Scientific Meeting
-
AbbVie (ABBV) Presents Positive Phase 3 SELECT-AXIS 2 Trials of Upadacitinib Results at EULAR 2022
